FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.